Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 1997

View Archived Issues

Bexxar now administered on outpatient basis

BioFocus and RDW begin collaboration for T-cell enzyme inhibitors

Safety study of Multikine in prostate cancer patients completed

PolyHeme blood substitute advances to phase III

Another Isis oligonucleotide enters clinical testing

Genzyme Transgenics, Bristol-Myers Squibb to codevelop second recombinant transgenic drug

Ortec's CCS advances in clinical development

Diatide's NDA for venous thrombosis detection kit accepted by FDA

NovaDx and REAADS Medical Products to merge

Tachykinin receptor antagonists developed at Janssen

RPR discloses new factor Xa inhibitors

Agents for enhancing erythropoiesis prepared at SmithKline Beecham

Bayer discloses inhibitors of leukotriene synthesis

SAR reported by Parke-Davis for series of N-type Ca2+ antagonists

LG Chemical characterizes new thrombin inhibitor

Excellent penetration of active parent compound in BALF following administration of GS-4104

Heat treatment for liver cancer assessed in clinical trials

Promising preliminary results obtained with Arthrovas in osteoarthritis

U.S. patent for antithrombotic agents issued to Burnham Institute

Reteplase and alteplase exhibit different profiles of fibrin binding at high doses

Letrozole approved in Canada

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...